01
Identify
We source controlled-release opportunities across healthcare: long-acting delivery, reformulation, and dosage-form innovation where adherence and access are the bottleneck.
Affordable controlled release
for healthcare.
The Trust in Life Initiative advances long-acting and controlled-release healthcare solutions through scientific leadership, purposeful partnerships, and execution built for real-world affordability.
Controlled release · move cursor to inspect
- Long-acting delivery heritage.
- Global healthcare perspective.
- Access-driven mindset.
- Execution across science, capital, and partnerships.
About
Controlled release, made accessible.
The Trust in Life Initiative exists to make controlled release more accessible, practical, and scalable across healthcare: turning long-acting delivery science into therapies that patients can actually reach, afford, and stay on.
Our purpose
We identify, shape, and support controlled-release opportunities that lower treatment burden and widen patient access, backing the science, the formulations, and the partnerships that move durable therapies from the lab into routine care.
Built on real experience
The Initiative draws on the experience of Anh Nguyen, a molecular biologist, business executive, and biotech entrepreneur whose career includes advancing companies to public listing in the United States. As a founder and former Chairman of MedinCell, he helped bring controlled-release innovation from early research to FDA-approved, long-acting therapy.
The heritage, in four phases
- I 1980s to early 1990s
Found
California biotech
- II 1990s to early 2000s
Equip
Invitrogen / Life Technologies
- III 2003 to 2024
Deliver
MedinCell
- IV 2024 →
Extend
Trust in Life Initiative
Heritage
A heritage in controlled release.
Built over time
This work is not defined by a single milestone, but by a platform and a conviction: that how a medicine is delivered matters as much as the molecule itself, and that delivery is where much of the patient benefit is won or lost.
Science with purpose
Under Anh Nguyen's leadership, MedinCell advanced its Controlled Release BEPO platform from early research to FDA approval in a major long-acting injectable therapy: proof that delivery science can be innovative, practical, and accessible at once.
From heritage to access
The Initiative extends that heritage into a clear mission: making controlled release affordable and scalable, so its benefits reach patients well beyond a single therapy or company.
Like the controlled-release platforms this heritage was built on, the work compounds quietly: steady doses of value, delivered where they matter most. Over years, not announcements.
Mandate
Mission & Vision.
Mission
We identify, shape, and support controlled-release opportunities that can lower treatment burden and widen patient access, with a focus on long-acting delivery, affordability at scale, and practical adoption.
Vision
A world where affordable controlled release is a standard tool of care, not a premium feature: where better delivery of proven and new medicines reduces burden, improves adherence, and reaches more patients at lower cost.
Guiding belief
The next step in healthcare is not only better molecules, but better, more affordable delivery of them.
Values
Five principles, released over time.
-
01
Innovation
We back practical controlled-release innovation: delivery that improves efficacy, lowers dosing burden, and holds up in real-world care, not only in the lab.
-
02
Responsibility
We believe leadership must be anchored in accountability, scientific rigor, and a long-term view of patient benefit.
-
03
Access
We prioritise therapies that can reach more people: affordable at scale, simple to administer, and viable beyond major treatment centres.
-
04
Stewardship
We protect what has been built and extend it, turning hard-won delivery science into durable, scalable healthcare value.
-
05
Collaboration
We expand access to long-acting and controlled-release therapies through scalable partnerships across science, capital, and industry.
Programs
How we build affordable controlled release.
02
Shape
We help shape programs toward affordability and scale: formulation choices, manufacturing reality, and regulatory discipline. Where a program needs sourcing, capital, or transactional support, our operational sister, Tili Consulting, carries it.
03
Support
We support adoption through partnerships across science, capital, and industry, so practical controlled-release therapies actually reach the patients and systems that need them.
Operational sister
Tili Consulting.
Sourcing · capital · diligence
tiliconsulting.ch
The execution arm for controlled-release programs
Visit Tili Consulting →
Tili Consulting is the operational, client-facing sister of the Trust in Life Initiative. It sources opportunities in the life-sciences space, introduces qualified counterparties, helps raise the capital that lets promising controlled-release programs move, and supports their development through diligence and beyond.
Contact
Partner with us.
For partnerships, programs, or enquiries: contact@tiliholding.com
For sourcing, capital, or diligence work, please reach our operational sister at tiliconsulting.ch .